Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Recently, recurrent activating mutations of NOTCH1 have been reported in up to 12% of CLL patients, underlining the relevance of NOTCH1 mutations (NOTCH1mut) as an independent negative prognostic marker. [1] [2] [3] NOTCH1mut in CLL are known to be located predominantly within the C-terminal PEST domain, frequently resulting in a truncated protein that is more stable than the wild-type one and activates the NOTCH1 signaling pathway. Accepted article preview online 17 July 2013; advance online publication, 9 August 2013
The aim of this study was to determine the frequency and prognostic impact of NOTCH1mut in CLL and to evaluate the range of mutational burden. We used the massively parallel amplicon next-generation deep-sequencing (NGS) technology (454 Life Sciences, Branford, CT, USA), enabling us to detect also low-level mutational clones, which have not been studied in detail yet. We here investigated a large unselected cohort of adult CLL patients for mutations in NOTCH1.
We information see Supplementary Table S1 ), collected at the UDMCC, Comprehensive Cancer Center, University of Salamanca, Spain.
As NOTCH1mut are known to be located predominantly within the C-terminal PEST domain, 1 we sequenced exons 33-34 (covering codons 2029-2556; Transcript-ID ENST00000277541), represented by seven distinct PCR assays with a median amplicon length of 345 bp (amplification protocol and primer sequences available in Supplementary Tables S2 and S3 ). In median, 602 bidirectional reads (range 243-2928) were generated per amplicon, thereby allowing a sensitive detection of variants with a lower limit of detection of 2%. 7, 8 In total, 113 NOTCH1mut were observed in 103/852 (12.1%) patients. All missense mutations were analyzed with the Polyphen-2, SIFT and MutationTaster algorithms [9] [10] [11] and were only included in downstream analyses if they were predicted as damaging. We identified 30 point mutations (12 missense and 18 nonsense; 26.5%) and 83 frame-shift alterations (82 deletions and 1 indel; 73.5%). The vast majority of mutations (97.3%) were heterozygous, only 3/113 mutations (2.7%) were homozygous. The most frequently occurring mutation was, as previously described, 1 p.Pro2514Argfs*4 (c.7541_7542delCT), which was identified in 76/113 (67.3%) variants. The median mutational burden was 32% (range: 2-71%). Of note, in 26/113 (23.0%) variations the mutation load was p10% and thus would not have been detected by direct capillary Sanger sequencing. No difference in clone size was detected between the p.Pro2514Argfs*4 hotspot mutations and other variants (mean hotspot ¼ 29.2%; mean remaining ¼ 33.1%; P ¼ 0.304). Interestingly, 10/103 (9.7%) NOTCH1mut patients carried two different mutations. In two cases, we could confirm both mutations belonging to different clones, as these mutations were located on distinct sequencing reads within the same amplicon (Supplementary Figure S1 ). In 9/10 patients, a different mutational load between the two NOTCH1mut was detected, indicating the presence of two independent clones or clonal evolution with acquisition of a second mutation in the initially NOTCH1 single-mutated clone. Of note, for none of these patients two independent populations were observed by immunophenotyping. None of the patients harbored more than two NOTCH1-mut. Mutations mainly clustered in the C-terminal part, that is, codons 2385-2555 of exon 34 where 102/113 (90.3%) alterations were located (Figure 1a) . All mutations are listed in Figure 1a and Supplementary Table S4 . Moreover, these data were confirmed in an independent validation cohort with 70 patients from Salamanca, Spain. As demonstrated in Figure 1b and Supplementary Figure S2 , both type and load (median: 25%, range: 3-55%) of NOTCH1mut was similar between the two cohorts and no significant differences were observed (P ¼ 0.83, Supplementary Figure S2) .
Confirming published data, 1 statistical analyses further revealed NOTCH1mut being significantly associated with unmutated (unmut) IGHV status (mut vs unmut: 23/514, 4.5% vs 80/338, 23.7%; Po0.001) and þ 12 as sole cytogenetic aberration Figure 2 . Kaplan-Meier analyses of time to treatment according to NOTCH1 mutation status in (a) the total cohort (clinical data available for n ¼ 643 cases), (b) the favorable prognostic risk group (IGHVmut, TP53unmut, n ¼ 365), (c) patients harboring the p.Pro2514Argfs*4 hotspot mutation (n ¼ 54) versus patients with other NOTCH1mut (n ¼ 21) and (d) NOTCH1 mutations with clone sizes p10% (n ¼ 23) versus clone sizes 410% (n ¼ 51).
(
001).
Regarding the co-occurence of NOTCH1 and TP53 mutations, it had been published that they tend to be mutually exclusive. 1 However, our analyses revealed that although the total number of both NOTCH1 and TP53 mutated patients was small (13 patients double-mutated/852 analyzed, 1.5%), a significant association between NOTCH1mut and TP53mut (P ¼ 0.04) was observed (Figure 1c) Figure 1c .
With respect to clinical data (available for n ¼ 643/852 cases, all from MLL), NOTCH1mut cases (n ¼ 74) showed a significantly shorter time to treatment (TTT) compared with NOTCH1 wild-type patients (n ¼ 569; median TTT 3.6 years vs 7.5 years, P ¼ 0.005; Figure 2a) . Even restricting the analysis to the favorable prognostic subgroup of patients (IGHVmut, TP53unmut, n ¼ 365), NOTCH1mut patients (n ¼ 19) still showed a significantly shorter TTT than NOTCH1 wild-type cases (n ¼ 346; median TTT 6.8 vs 8.8 years, P ¼ 0.02), indicating that NOTCH1 represents a negative prognostic factor allowing to further discriminate this favorable CLL subset (Figure 2b) . No difference in TTT was observed between the hotspot mutation p.Pro2514Argfs*4 and other NOTCH1mut (P ¼ 0.48, Figure 2c ). Strikingly, even small subclones with NOTCH1mut p10 versus 410% demonstrated the same outcome (P ¼ 0.86, Figure 2d ). Univariate Cox regression analyses of TTT revealed an adverse prognostic impact for NOTCH1mut (P ¼ 0.006; hazard ratio (HR) ¼ 1.64) and TP53mut (P ¼ 0.004; HR ¼ 1.8). A favorable prognosis was observed for IGHVmut (Po0.001; HR ¼ 0.312) and del(13q) (P ¼ 0.034; HR ¼ 0.76). However, in multivariate analyses only IGHVmut (Po0.001; HR ¼ 0.32) and TP53mut (P ¼ 0.043; HR ¼ 1.51) were identified as independent prognostic markers.
In conclusion, we here present the first deep-sequencing study of NOTCH1 mutations in a large unselected CLL cohort and report an overall mutation frequency of 12.1%. Remarkably, 32.7% of the observed mutations represented disruptive variants different from the known hotspot mutation p.Pro2514Argfs*4. Further, the mutational burden was found to be p10% in 23.0% of patients with NOTCH1 mutations and therefore is below the Sanger sequencing detection limit in nearly 1/4 of all patients. We could confirm that NOTCH1 mutations are an adverse prognostic parameter associated with shorter TTT. As it has been shown that NOTCH1 mutations not only negatively influence TTT, but also increase the risk of progression and refractoriness to therapy, [1] [2] [3] 13, 14 it is crucial to detect NOTCH1 mutations as early as possible to adjust therapy. As a deepsequencing assay is mandatory to detect low-level mutational clones, it is suggested to prefer this technology in order to adequately characterize the patients' genetic profile early during its course.
